Employees: 2,110
Size Shanghai Haohai Biological Technology (688366.SS) is a China Health Care company (Medical Distributors) with a market value of $878M, the 2413th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.00 on 18 Nov 2026.
Performance Over six months the shares fell 23.9%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 9.4% over the last twelve months (peer median +5.3%); the operating margin is -2.1% (peer median 2.3%).
Valuation It trades at 16.2× forward earnings against a peer median of 15.3× (5th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.3 points below its cost of capital (7.7% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.28B | CN¥2.46B | CN¥2.68B | CN¥2.64B | CN¥2.12B |
| Revenue growth | — | -8% | +2% | +25% | — |
| Gross profit | CN¥1.60B | CN¥1.60B | CN¥1.74B | CN¥1.74B | CN¥1.32B |
| EBITDA | n/a | CN¥456M | CN¥580M | CN¥597M | CN¥372M |
| Net income | CN¥109M | CN¥251M | CN¥420M | CN¥416M | CN¥180M |
| Free cash flow | CN¥272M | CN¥458M | CN¥362M | CN¥402M | -CN¥34.1M |
| Capital expenditure | CN¥204M | CN¥187M | CN¥363M | CN¥267M | CN¥317M |
| Total debt | CN¥433M | CN¥398M | CN¥453M | CN¥408M | CN¥118M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688366.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -3.1% | 6th lowest of 21 |
| 6-month return | -23.9% | -2.3% | 6th lowest of 21 |
| Distance from 52-week high | -47.0% | -20.2% | 4th lowest of 21 |
| Revenue growth (TTM) | -9.4% | +5.3% | 4th lowest of 21 |
| Operating margin | -2.1% | 2.3% | 4th lowest of 21 |
| Forward P/E | 16.2× | 15.3× | 5th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 16.9% | -1.2% | 4th most demanding of 16 |
| Growth delivered (Del g) | +13.2% | +5.7% | 3rd highest of 16 |
| Hurdle (Req g minus delivered) | +3.8 pp | -6.3 pp | 4th most demanding of 16 |
| ROIC minus cost of capital | -5.3 pp | +0.0 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 16.2× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | n/a | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | n/a | 58.3% | -7.8% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | n/a | -1.2% | +5.7% |